Therapy of nonalcoholic fatty liver disease: current status.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 20388946)

Published in J Physiol Pharmacol on December 01, 2009

Authors

M Duvnjak1, V Tomasic, M Gomercic, L Smircic Duvnjak, N Barsic, I Lerotic

Author Affiliations

1: Division of Gastroenterology and Hepatology, Department of Medicine Sestre Milosrdnice University Hospital, Zagreb, Croatia. marko.duvnjak1@gmail.com

Articles citing this

Template to improve glycemic control without reducing adiposity or dietary fat. Am J Physiol Endocrinol Metab (2011) 1.25

Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96

Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol (2014) 0.96

How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? Hepat Mon (2013) 0.88

A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci (2016) 0.87

Role of Pin1 protein in the pathogenesis of nonalcoholic steatohepatitis in a rodent model. J Biol Chem (2012) 0.85

Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol (2012) 0.83

Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats. Res Pharm Sci (2015) 0.81

Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81

Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr (2013) 0.80

Effects of physical activity upon the liver. Eur J Appl Physiol (2014) 0.79

Metformin is a novel suppressor for transforming growth factor (TGF)-β1. Sci Rep (2016) 0.78

The Effect of Chlorella vulgaris Supplementation on Liver En-zymes, Serum Glucose and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease. Health Promot Perspect (2014) 0.76

The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res (2017) 0.75